-
-
-
The Expanding Benefits of GLP-1 Medicines
Diabetes
Discover the expanding benefits of GLP-1 drugs beyond diabetes and obesity, including improvements in heart, kidney, liver, joint, brain health, and more, as summarized by GLP-1 pioneer Daniel J. Drucker.
-
EU Confirms Vision Risk Tied to Semaglutide
EMA
EU regulators have confirmed a rare risk of vision loss linked to Novo Nordisk’s semaglutide, used in Wegovy and Ozempic. Drug labels will be updated to reflect the potential for NAION, a serious but very rare eye condition.
-
-
Top 10 Best-Selling Drugs in Q1 2025
Market Trend
Discover the top 10 best-selling drugs of Q1 2025. GLP-1 drugs dominate, with semaglutide and tirzepatide leading growth. Oncology and autoimmune treatments face challenges amid rising competition and patent expirations.
-
-
-
-
佛冈县|
界首市|
科尔|
泸州市|
上饶县|
长治县|
扎囊县|
鹿邑县|
天津市|
青神县|
扎兰屯市|
剑川县|
南昌县|
贺兰县|
荥阳市|
兰州市|
盐城市|
防城港市|
五原县|
绥宁县|
吉木萨尔县|
鹿泉市|
浮梁县|
蓬安县|
乌鲁木齐县|
东山县|
澄迈县|
波密县|
科尔|
奈曼旗|
大丰市|
安福县|
舞阳县|
邛崃市|
余庆县|
台北市|
鄂温|
南涧|
禄劝|
香港
|
醴陵市|